Evidence map›Paper›PMID 39510069›Full record

ArticleCell reports. Medicine2024

Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer.

Michael J Campbell, Denise M Wolf, Christina Yau, Lamorna Brown-Swigart, Julie Wulfkuhle, Isela R Gallagher, Zelos Zhu, Jennifer Bolen, Scott Vandenberg, Clifford Hoyt and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Michael J CampbellDepartment of Surgery, University of California, San Francisco, San Francisco, CA 94143, USA. Electronic address: michael.campbell@ucsf.edu.
Denise M WolfDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.
Christina YauDepartment of Surgery, University of California, San Francisco, San Francisco, CA 94143, USA.
Lamorna Brown-SwigartDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.
Julie WulfkuhleCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA 20110, USA.
Isela R GallagherCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA 20110, USA.
Zelos ZhuDepartment of Surgery, University of California, San Francisco, San Francisco, CA 94143, USA.
Jennifer BolenBiospecimen Resource Program (BIOS), University of California, San Francisco, San Francisco, CA 94143, USA.
Scott VandenbergDepartment of Pathology, University of California, San Francisco, San Francisco, CA 94143, USA.
Clifford HoytAkoya Biosciences, Marlborough, MA 01752, USA.
Hidetoshi MoriCenter for Immunology and Infectious Diseases, University of California, Davis, Davis, CA 95616, USA.
Alexander BorowskyCenter for Immunology and Infectious Diseases, University of California, Davis, Davis, CA 95616, USA; Department of Pathology and Laboratory Medicine, University of California Davis, Sacramento, CA 95817, USA.
Laura SitDepartment of Surgery, University of California, San Francisco, San Francisco, CA 94143, USA.
Jane PerlmutterGemini Group, Ann Arbor, MI 48107, USA.
Smita M AsareQuantum Leap Healthcare Collaborative, San Francisco, CA 94118, USA.
I-SPY2 Investigators
Rita NandaDepartment of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL 60637, USA.
Minetta C LiuDepartment of Surgery, Mayo Clinic, Rochester, MN 55905, USA.
Douglas YeeDepartment of Medicine, University of Minnesota, Minneapolis, MN 55455, USA.
Angela M DeMichelePerelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Nola M HyltonDepartment of Radiology, University of California, San Francisco, San Francisco, CA 94143, USA.
Lajos PusztaiYale School of Medicine, Yale University, New Haven, CT 06510, USA.
Donald A BerryBerry Consultants, LLC, Austin, TX 78746, USA.
Gillian L HirstDepartment of Surgery, University of California, San Francisco, San Francisco, CA 94143, USA.
Emanuel F PetricoinCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA 20110, USA.
Laura Van't VeerDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.
Laura EssermanDepartment of Surgery, University of California, San Francisco, San Francisco, CA 94143, USA.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
The I SPY 2.2 TRIAL: Evolving to Imaging and Molecular Biomarker Response Directed Adaptive Sequential Treatment to Optimize Breast Cancer OutcomesP01CA210961 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Nola M. Hylton-Watson · 2017 to 2026
$22.9M
NCATS NIH HHS UL1 TR001863NCI NIH HHS P01 CA210961
6 · The paper itself

Abstract

Only a subset of patients with breast cancer responds to immune checkpoint blockade (ICB). To better understand the underlying mechanisms, we analyze pretreatment biopsies from patients in the I-SPY 2 trial who receive neoadjuvant ICB using multiple platforms to profile the tumor microenvironment. A variety of immune cell populations and markers of immune/cytokine signaling associate with pathologic complete response (pCR). Interestingly, these differ by breast cancer receptor subtype. Measures of the spatial distributions of immune cells within the tumor microenvironment, in particular colocalization or close spatial proximity of PD-1

Indexed as

Biomarkers, TumorBreast NeoplasmsImmune Checkpoint InhibitorsNeoadjuvant TherapyTumor MicroenvironmentB7-H1 AntigenFemaleHumansMiddle AgedNeoplasm StagingProgrammed Cell Death 1 ReceptorTreatment OutcomeB7-H1 AntigenBiomarkers, TumorImmune Checkpoint InhibitorsProgrammed Cell Death 1 Receptorbreast cancerimmune checkpoint blockademultiplex immunofluorescencepredictive markersspatial metrics

Identifiers

PMID39510069
PMCPMC11604542

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.